Early Angiography for High-Risk Acute Coronary Syndromes

In an observational analysis, longer delays were associated with increased risk for adverse events.

Although an early invasive strategy is generally recommended for patients with acute coronary syndromes at high risk for adverse events (Journal Watch Cardiology Sep 12 2007), the optimal timing of angiography is not known. In this retrospective analysis of data from the SYNERGY trial, a manufacturer-funded study of enoxaparin versus unfractionated heparin in early intervention for non–ST-segment-elevation ACS, investigators examined the relation between time to angiography (in 6-hour intervals) and outcomes in 6352 ACS patients who underwent coronary angiography within 48 hours of hospital admission.

Angiography was performed earlier in patients who were relatively young; had no history of MI and percutaneous coronary intervention; had ST-s…

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI